Nat Biotechnology：科学家成功激活无效HIV抗体

2014-01-02 张笑编译中国科学报

《自然—生物技术》上的一项报告介绍了一种可重新激活已被HIV产生抗药性的治疗抗体的方法。除了介绍改造抗体以使其重新对大批HIV-1病毒株有效的改进方法外，报告作者还认为这种改进方法对其他治疗抗体也会有用。此次研究涉及到的抗体名为ibalizumab，通过阻断HIV-1为进入细胞而使用的一种受体的方式发挥作用。但是，某些病人体内的HIV-1病毒株在受到ibalizumab作用时，会发生一

《自然—生物技术》上的一项报告介绍了一种可重新激活已被HIV产生抗药性的治疗抗体的方法。除了介绍改造抗体以使其重新对大批HIV-1病毒株有效的改进方法外，报告作者还认为这种改进方法对其他治疗抗体也会有用。

此次研究涉及到的抗体名为ibalizumab，通过阻断HIV-1为进入细胞而使用的一种受体的方式发挥作用。但是，某些病人体内的HIV-1病毒株在受到ibalizumab作用时，会发生一些特殊突变从而对抗体产生抵抗性。结构性研究显示，这些突变会通过在病毒与抗体之间引入空隙的方式来弱化HIV-1和ibalizumab之间的相互作用。

因为怀疑这种空隙有利于HIV-1产生抗药性，David Ho等人推断将其“重新填充”可能会阻止病毒的侵入动作。为了验证假设，他们在ibalizumab与病毒产生反应的位置附近标记上一种碳水化合物。结果，标记后的抗体100%中和了试验用到的HIV-1病毒株，其中包括那些之前已对原始抗体产生了抗药性的病毒。

原文出处：

Ruijiang Song, Deena A Oren, David Franco, Michael S Seaman& David D Ho. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1 –neutralizing activity. Nature Biotechnology, 06 October 2013; doi:10.1038/nbt.2677【原文下载】

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
2014-11-16 sunylz

#Bio#

54 0
[GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
2014-04-23 Homburg

#HIV抗体#

74 0
[GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
2014-12-18 shock_melon

#TEC#

63 0
[GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
2014-02-05 fzwish20000

#Technology#

63 0
[GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
2014-06-18 cathymary

#Biotech#

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
2014-11-11 liye789132251

#Nat#

51 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

感染

Nat Biotechnology：科学家成功激活无效HIV抗体

相关资讯

科室

工具

服务